RobertJFramMD

PubMed

• 41 citations
  Pevonedistat plus azacitidine vs azacitidine alone in higher-risk MDS/chronic myelomonocytic leukemia or low-blast-percentage AML.
  Lionel Adès, Larisa Girshova, Vadim A Doronin, María Díez-Campelo, David Valcárcel, Suman Kambhampati, Nora-Athina Viniou, Dariusz Woszczyk, Raquel De Paz Arias, Argir...> ;Blood Advances. 2022 Sep 13
• 2 citations
  Correction to: Randomized phase 2 trial of pevonedistat plus azacitidine versus azacitidine for higher-risk MDS/CMML or low-blast AML.
  Mikkael A. Sekeres, Justin M. Watts, Atanas Radinoff, Montserrat Arnan Sangerman, Marco Cerrano, Patricia Font Lopez, Joshua F. Zeidner, Maria Diez Campelo, Carlos Gra...> ;Leukemia. 2021 Nov 17
• 8 citations
  Measuring patient-reported physical functioning and fatigue in myelodysplastic syndromes using a modular approach based on EORTC QLQ-C30.
  Antoine Regnault, Farrah Pompilus, Anna Ciesluk, Flora Mazerolle, Rafael Bejar, Robert J. Fram, Douglas V. Faller, Patrick Marquis, Jill A Bell> ;Journal of Patient-Reported Outcomes. 2021 Jul 20
• 67 citations
  Randomized phase 2 trial of pevonedistat plus azacitidine versus azacitidine for higher-risk MDS/CMML or low-blast AML.
  Mikkael A. Sekeres, Justin M. Watts, Atanas Radinoff, Montserrat Arnan Sangerman, Marco Cerrano, Patricia Font Lopez, Joshua F. Zeidner, Maria Diez Campelo, Carlos Gra...> ;Leukemia. 2021 Jan 22
• 11 citations
  A pragmatic patient-reported outcome strategy for rare disease clinical trials: application of the EORTC item library to myelodysplastic syndromes, chronic myelomonocy...
  Jill A Bell, Aaron Galaznik, Farrah Pompilus, Sara Strzok, Rafael Bejar, Fatima Scipione, Robert J. Fram, Douglas V. Faller, Stefan J. Cano, Patrick Marquis> ;Journal of Patient-Reported Outcomes. 2019 Jun 19
• 11 citations
  Economic Burden of Patients Treated for Higher-Risk Myelodysplastic Syndromes (HR-MDS) in Routine Clinical Care in the United States
  Jill A Bell, Aaron Galaznik, Marlo Blazer, Huai-Che Shih, Eileen Farrelly, Augustina Ogbonnaya, Michael Eaddy, Robert J. Fram, Douglas V. Faller> ;Pharmacoeconomics - Open. 2019 Jun 1
• 11 citations
  A retrospective study evaluating treatment patterns and survival outcomes in elderly patients with acute myeloid leukemia treated in the United States with either 7+3 ...
  Jill A Bell, Aaron Galaznik, Eileen Farrelly, Marlo Blazer, Sharanya Murty, Augustina Ogbonnaya, Michael Eaddy, Robert J. Fram, Douglas V. Faller, Vamsi Kota> ;Leukemia Research. 2019 Mar 1
• 19 citations
  Economic burden of elderly patients with acute myeloid leukemia treated in routine clinical care in the United States.
  Jill A Bell, Aaron Galaznik, Eileen Farrelly, Marlo Blazer, Sharanya Murty, Augustina Ogbonnaya, Michael Eaddy, Robert J. Fram, Douglas V. Faller, Vamsi Kota> ;Leukemia Research. 2018 Aug 1
• 10 citations
  Effectiveness and Safety of Therapeutic Regimens for Elderly Patients With Acute Myeloid Leukemia: A Systematic Literature Review
  Jill A Bell, Aaron Galaznik, Rachel Huelin, Michael Stokes, Yelan Guo, Robert J. Fram, Douglas V. Faller> ;Clinical Lymphoma, Myeloma & Leukemia. 2018 Jul 1
• 13 citations
  Systematic Literature Review of Treatment Options and Clinical Outcomes for Patients With Higher-Risk Myelodysplastic Syndromes and Chronic Myelomonocytic Leukemia.
  Jill A Bell, Aaron Galaznik, Rachel Huelin, Michael Stokes, Yelan Guo, Robert J. Fram, Douglas V. Faller> ;Clinical Lymphoma, Myeloma & Leukemia. 2018 Apr 1
• 25 citations
  Pharmacokinetics and Antitumor Efficacy of XMT-1001, a Novel, Polymeric Topoisomerase I Inhibitor, in Mice Bearing HT-29 Human Colon Carcinoma Xenografts
  Mark D. Walsh, Suzan K. Hanna, Jeremy M. Sen, S. Rawal, Carolina B. Cabral, Aleksandr V. Yurkovetskiy, Robert Fram, Timothy B. Lowinger, William C. Zamboni> ;Clinical Cancer Research. 2012 May 1
• 51 citations
  XMT-1001, a novel polymeric camptothecin pro-drug in clinical development for patients with advanced cancer.
  Alexander V. Yurkovetskiy, Robert Fram> ;Advanced Drug Delivery Reviews. 2009 Nov 12
• 29 citations
  A Phase I Study of the Dolastatin-15 Analogue Tasidotin (ILX651) Administered Intravenously Daily for 5 Consecutive Days Every 3 Weeks in Patients with Advanced Solid ...
  Scot W. Ebbinghaus, Eric J. Rubin, Evan M. Hersh, Lee D. Cranmer, Peter L. Bonate, Robert J. Fram, Antti Jekunen, Steven D. Weitman, Lisa A. Hammond> ;Clinical Cancer Research. 2005 Nov 1
• 29 citations
  Phase I and pharmacokinetic study of the dolastatin-15 analogue tasidotin (ILX651) administered intravenously on days 1, 3, and 5 every 3 weeks in patients with advanc...
  Casey Cunningham, Leonard Joseph Appleman, Miora Kirvan-Visovatti, David P. Ryan, Eileen Regan, Svetislava J. Vukelja, Peter L. Bonate, Francis Ruvuna, Robert J. Fram,...> ;Clinical Cancer Research. 2005 Nov 1
• 54 citations
  Novel inosine monophosphate dehydrogenase inhibitor VX-944 induces apoptosis in multiple myeloma cells primarily via caspase-independent AIF/Endo G pathway.
  Kenji Ishitsuka, Teru Hideshima, Makoto Hamasaki, Noopur Raje, Shaji Kumar, Klaus Podar, Steven Le Gouill, Norihiko Shiraishi, Hiroshi Yasui, Aldo M. Roccaro, Yu Zu Ta...> ;Oncogene. 2005 Sep 1
• 93 citations
  A clinically relevant SCID-hu in vivo model of human multiple myeloma.
  Pierfrancesco Tassone, Paola Neri, Daniel R. Carrasco, Renate Burger, Victor S. Goldmacher, Robert J. Fram, Vidit Munshi, Masood A. Shammas, Laurence Catley, GS Jacob,...> ;Blood. 2004 Nov 16
• 38 citations
  Antineoplastic effects of chemotherapeutic agents are potentiated by NM-3, an inhibitor of angiogenesis
  Corinne L. Reimer, Naoki Agata, Jennifer Tammam, Michael Bamberg, William M. Dickerson, George D. Kamphaus, Susan L. Rook, Michael Milhollen, Robert Fram, Raghu Kallur...> ;Cancer Research. 2002 Feb 1
• 19 citations
  Phase I and Pharmacokinetic Study of LU79553, a DNA Intercalating Bisnaphthalimide, in Patients With Solid Malignancies
  Miguel A. Villalona-Calero, Joseph Paul Eder, Deborah Toppmeyer, Lee F. Allen, Robert Fram, Raja Velagapudi, Michael Myers, Anthony A. Amato, Kathleen Kagen-Hallet, Be...> ;Journal of Clinical Oncology. 2001 Feb 1
• 22 citations
  A phase I clinical and pharmacokinetic study of the dolastatin analogue cemadotin administered as a 5-day continuous intravenous infusion
  Jeffrey G. Supko, Thomas J. Lynch, Jeffrey W. Clark, Robert Fram, Lee F. Allen, Raja Velagapudi, Donald Kufe, Joseph Paul Eder> ;Cancer Chemotherapy and Pharmacology. 2000 Jan 1
• Phase I study of the orally administered butyrate prodrug, tributyrin, in patients with solid tumors.
  Conley BA, Egorin MJ, Tait N, Rosen DM, Sausville EA, Dover G, Fram RJ, Van Echo DA> ;Clin. Cancer Res.. 1998-03-01
• 28 citations
  Interactions of cis-Diamminedichloroplatinum(II) with 1-β-d-Arabinofuranosylcytosine in LoVo Colon Carcinoma Cells
  Robert Fram, Norman Robichaud, Sheldon D. Bishov, John M. Wilson> ;Cancer Research. 1987 Jul 1
• 27 citations
  Effect of 1-β-D-arabinofuranosyl cytosine and hydroxyurea on the repair of X-ray-induced DNA single-strand breaks in human leukemic blasts
  Robert Fram, Donald Kufe> ;Biochemical Pharmacology. 1985 Jul 15
• 8 citations
  Clinical, pathologic and immunologic features of patients with non‐Hodgkin's lymphoma in a leukemic phase. A retrospective analysis of 34 patients
  Robert J. Fram, Arthur T. Skarin, David S. Rosenthal, Geraldine S. Pinkus, Lee M. Nadler> ;Cancer. 1983 Oct 1
• 34 citations
  Biologic effect of 5-fluoro-2′-deoxyuridine incorporation in L1210 deoxyribonucleic acid☆
  Donald Kufe, Peter Scott, Robert Fram, Pierre Major> ;Biochemical Pharmacology. 1983 Apr 15
• 11 citations
  A phase I-II study of combination therapy with thymidine and cytosine arabinoside.
  Robert Fram, Pierre Major, E. Egan, P. Beardsley, D. Rosenthal, Donald Kufe> ;Cancer Chemotherapy and Pharmacology. 1983 Jan 1
• Join now to see all